Exhibit 10.24.7
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*],
HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
AMENDMENT NO. 10
TO THE
COLLABORATION AGREEMENT
This Amendment No. 10 to the Collaboration Agreement (this “Amendment”) is entered into as
of the 23rd day of June, 2026 (the “Amendment Effective Date”) by and between Amgen Inc.,
a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks,
California 91320 (“Amgen”), and AstraZeneca Collaboration Ventures, LLC, a Delaware
limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware
19850 (“Partner”). Amgen and Partner are sometimes referred to herein individually as a
“Party” and collectively as the “Parties”.
WHEREAS, Amgen and Partner entered into that certain Collaboration Agreement, dated as of
March 30, 2012, as amended by Amendment No.1 to the Collaboration Agreement, dated
…